Caraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failure
Caraco Pharmaceutical Laboratories is recalling 91,777 bottles of Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, because stability results showed the product did not meet drug release dissolution specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, and the source text does not report any illnesses, injuries, or hospitalizations, fitting the criteria for a moderate severity recall involving a potential quality defect without reported harm.
Plain-English summary
Caraco Pharmaceutical Laboratories, Ltd. is recalling 91,777 bottles of Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg. The affected products are packaged in 30-count bottles (NDC 41616-760-83) and 90-count bottles (NDC 41616-760-81). The recall is due to stability results indicating that the product did not meet the drug release dissolution specifications.
The affected lots include JKL4344A, JKL5460A, and JKL5458A for the 30-count bottles, and JKL4344B, JKL5460B, and JKL5458B for the 90-count bottles. All affected lots have expiration dates of 07/14, 10/14, or 11/14. The products were distributed nationwide and in Puerto Rico.
Consumers and healthcare providers should stop using the affected products and contact their healthcare provider for further instructions. The recall is classified as FDA Class II, which means the use of, or exposure to, the product may cause temporary or medically reversible adverse health consequences.
The recalled product
- Product
- Venlafaxine Hydrochloride Extended-Release Tablets, 37.5 mg, packaged in a) 30-count bottles (NDC 41616-760-83, UPC 3 41616 76083 5); and b) 90-count bottles (NDC 41616-760-81, UPC 3 41616 76081 1), Rx only, Distributed by: Caraco Pharmaceutical Laboratories, Ltd., 1150 Elijah Mc
- Manufacturer
- Caraco Pharmaceutical Laboratories, Ltd.
- Category
- Drug — Antidepressant
- Hazard
- Affected units
- 91,777
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (10)
- Lot #: a) JKL4344A
- Exp 07/14
- JKL5460A
- Exp 10/14
- JKL5458A
- Exp 11/14
- b) JKL4344B
- JKL5460B
- JKL5458B
- Exp 11/14.
Distribution
Part of a larger recall action
This product is one of 2 recalled by Caraco Pharmaceutical Laboratories, Ltd. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Caraco Pharmaceutical Laboratories, Ltd.
See all →- ModerateCaraco Recalls Cephalexin Capsules Due to Manufacturing Deviations
FDA (Drugs) · 2014-08-13
- ModerateCaraco Recalls Cephalexin Capsules Due to Manufacturing Practice Deviations
FDA (Drugs) · 2014-08-13
- ModerateCaraco Recalls Venlafaxine Hydrochloride Extended-Release Tablets for Dissolution Failures
FDA (Drugs) · 2014-07-09
- SevereCaraco Recalls Gemcitabine Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2014-07-02
- ModerateCaraco Recalls Children's Cetirizine Tablets Due to Impurity Failures
FDA (Drugs) · 2014-05-07
Same hazard · dissolution failure
See all →- ModerateApotex Recalls Paxil Tablets for Failed Dissolution and Stability Testing
FDA (Drugs) · 2026-09-02
- ModerateMylan Recalls Acamprosate Calcium Tablets Due to Dissolution Failure
FDA (Drugs) · 2026-08-26
- ModerateChlorthalidone 25mg tablets failed dissolution specifications in two batches
FDA (Drugs) · 2026-06-24
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- ModerateMinocycline extended-release tablets failed dissolution testing during stability analysis
FDA (Drugs) · 2026-06-17